Published On: Wed, Oct 19th, 2016

Shares Of Horizon Discovery Group (LON:HZD) Rated As Buy By Analysts At Numis

According to an update released by analysts at numis the broker has now set a ‘Buy’ rating on shares of Horizon Discovery Group (LON:HZD) with a price target of 260.

numis on Wednesday reiterated Horizon Discovery Group’s analyst rating as ‘Buy’ with its price target of 260 highlighting a potential increase of 89.16% from Horizon Discovery Group’s current price of 137.45.


Over the last twelve months Horizon Discovery Group’s stock price has decreased from 150 to 137.45, a change of -8.37%.

Horizon Discovery Group has 94,122,000 shares in issue which have a share price of 137.45 giving Horizon Discovery Group a market capitalisation of 129.37M GBp.

The company has a 50 day moving average of 155.99 and a 200 day moving average of 159.66. The 52 week high shares of Horizon Discovery Group have reached is 188.06 whilst the 52 week low for the company’s shares is 125.

Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer. These models have been adopted by c1,400 organizations to better understand of the genetic drivers of disease, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.